Madrigal Pharmaceuticals Publication in the New England Journal of Medicine
Resmetirom is the first investigational medicine for NASH to achieve fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial

Detailed analyses reinforce the safety profile of resmetirom

Resmetirom has the potential to become the first and only medicine approved for NASH; PDUFA date is March 14, 2024

Today, February 8, 2024, Madrigal Pharmaceuticals (This content is for paid subscribers.